Henry Ford Health

Henry Ford Health Scholarly Commons
Radiation Oncology Articles

Radiation Oncology

3-5-2021

A Multi-Institutional Analysis of Adjuvant Chemotherapy and
Radiation Sequence in Women With Stage IIIC Endometrial
Cancer
Lara Hathout
Yaqun Wang
Qingyang Wang
Irina Vergalasova
Mohamed A. Elshaikh
Henry Ford Health, MELSHAI1@hfhs.org

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/radiationoncology_articles

Recommended Citation
Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S,
Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo
AL, Lea JS, Albuquerque KV, and Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and
Radiation Sequence in Women with Stage IIIC Endometrial Cancer. Int J Radiat Oncol Biol Phys 2021.

This Article is brought to you for free and open access by the Radiation Oncology at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Radiation Oncology Articles by an authorized administrator of
Henry Ford Health Scholarly Commons.

Authors
Lara Hathout, Yaqun Wang, Qingyang Wang, Irina Vergalasova, Mohamed A. Elshaikh, Irina Dimitrova,
Shari Damast, Jessie Y. Li, Emma C. Fields, Sushil Beriwal, Andrew Keller, Elizabeth A. Kidd, Melissa Usoz,
Shruti Jolly, Elizabeth Jaworski, Eric W. Leung, Elysia Donovan, Neil K. Taunk, Junzo Chino, Divya Natesan,
Andrea L. Russo, Jayanthi S. Lea, Kevin V. Albuquerque, and Larissa J. Lee

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
radiationoncology_articles/315

www.redjournal.org

Clinical Investigation

A Multi-Institutional Analysis of Adjuvant
Chemotherapy and Radiation Sequence in
Women With Stage IIIC Endometrial Cancer
Lara Hathout, MD,* Yaqun Wang, PhD,* Qingyang Wang,*
Irina Vergalasova, PhD,* Mohamed A. Elshaikh, MD,y
Irina Dimitrova, MD,z Shari Damast, MD,x Jessie Y. Li, MD,x
Emma C. Fields, MD,k Sushil Beriwal, MD,{ Andrew Keller, MD,{
Elizabeth A. Kidd, MD,# Melissa Usoz,# Shruti Jolly, MD,**
Elizabeth Jaworski, MD,** Eric W. Leung, MD,yy Elysia Donovan, MD,yy
Neil K. Taunk, MD,zz Junzo Chino, MD,xx Divya Natesan, MD,xx
Andrea L. Russo, MD,kk Jayanthi S. Lea, MD,{{
Kevin V. Albuquerque, MD,{{ and Larissa J. Lee, MD##
*Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey; Departments of yRadiation
Oncology and zGynecologic Oncology, Henry Ford Cancer Institute, Detroit, Michigan; xDepartment of
Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut; kDepartment of Radiation
Oncology, Virginia Commonwealth University Health System, Massey Cancer Center, Richmond,
Virginia; {Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh
School of Medicine, Pittsburgh, Pennsylvania; #Department of Radiation Oncology, Stanford
University School of Medicine, Stanford, California; **Department of Radiation Oncology, University
of Michigan, Ann Arbor, Michigan; yyDepartment of Radiation Oncology, Odette Cancer Centre,
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; zzDepartment of
Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia,
Pennsylvania; xxDepartment of Radiation Oncology, Duke University Medical Center, Durham, North
Carolina; kkDepartment of Radiation Oncology, Massachusetts General Hospital, Boston,
Massachusetts; {{Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical
Center, Dallas, Texas; and ##Department of Radiation Oncology, Brigham and Women’s Hospital and
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Received Nov 3, 2020, and in revised form Feb 21, 2021. Accepted for publication Feb 28, 2021.

Corresponding author: Lara Hathout, MD; E-mail: lh547@cinj.rutgers.
edu
Disclosures: The authors declare no conflict of interest in regard to this
manuscript.

Data sharing statement: Research data are stored in an institutional
repository and will be shared upon request to the corresponding author.

Int J Radiation Oncol Biol Phys, Vol. -, No. -, pp. 1e9, 2021
0360-3016/$ - see front matter Ó 2021 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.ijrobp.2021.02.055

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on April 26, 2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

2

Hathout et al.

International Journal of Radiation Oncology  Biology  Physics

Purpose: Our purpose was to evaluate the effect of sequence and type of adjuvant therapy for patients with stage IIIC endometrial carcinoma (EC) on outcomes.
Methods and Materials: In a multi-institutional retrospective cohort study, patients with stage IIIC EC who had surgical staging and received both adjuvant chemotherapy and radiation therapy (RT) were included. Adjuvant treatment regimens were
classified as adjuvant chemotherapy followed by sequential RT (upfront chemo), which was predominant sequence; RT with
concurrent chemotherapy followed by chemotherapy (concurrent); systemic chemotherapy before and after RT (sandwich);
adjuvant RT followed by chemotherapy (upfront RT); or chemotherapy concurrent with vaginal cuff brachytherapy alone
(chemo-brachy). Overall survival (OS) and recurrence-free survival (RFS) rates were estimated by the Kaplan-Meier method.
Results: A total of 686 eligible patients were included with a median follow-up of 45.3 months. The estimated 5-year OS and
RFS rates were 74% and 66%, respectively. The sequence and type of adjuvant therapy were not correlated with OS or RFS
(adjusted P Z .68 and .84, respectively). On multivariate analysis, black race, nonendometrioid histology, grade 3 tumor,
stage IIIC2, and presence of adnexal and cervical involvement were associated with worse OS and RFS (all P < .05). Regardless of the sequence of treatment, the most common site of first recurrence was distant metastasis (20.1%). Vaginal only, pelvic only, and paraortic lymph node (PALN) recurrences occurred in 11 (1.6%),15 (2.2 %), and 43 (6.3 %) patients,
respectively. Brachytherapy alone was associated with a higher rate of PALN recurrence (15%) compared with external beam
radiation therapy (5%) P < .0001.
Conclusions: The sequence and type of combined adjuvant therapy did not affect OS or RFS rates. Brachytherapy alone was
associated with a higher rate of PALN recurrence, emphasizing the role of nodal radiation for stage IIIC EC. The vast
proportion of recurrences were distant despite systemic chemotherapy, highlighting the need for novel regimens. Ó 2021
Elsevier Inc. All rights reserved.

Introduction
Endometrial cancer (EC) is the fourth most common cancer
in women, with an estimated annual incidence of 65,620
new cases in the United States in 2020 and approximately
12,590 deaths.1 Unlike many solid tumors, the incidence of
EC has continued to increase the last several decades1 and
has been attributed to a decline in fertility rates, exogenous
estrogen, diabetes, and obesity.2,3 A recent populationbased study that controlled for hysterectomy prevalence
found that an increase in the age-adjusted incidence of
nonendometrioid histologies across all races was responsible for this trend, and non-Hispanic black women had the
lowest survival rates for all stages and histologies.4
Although locally advanced EC with lymph node
metastasis only represents 8% to 10% of all EC cases,5,6
recurrence rates are high despite adjuvant therapy, which
translates into poor 5-year overall survival (OS) rates,
ranging between 50% and 60%.5 Adjuvant radiation
therapy (RT) has been shown to reduce pelvic recurrence
while chemotherapy reduces distant metastasis,7 hence the
rationale of combining both treatments to maximize
locoregional and distant control. The recently published
Post-Operative Radiation Therapy in Endometrial Cancer
trial (PORTEC) 3 trial reported an OS benefit with the
addition of chemotherapy during and after radiation
compared with pelvic radiation therapy alone in high-risk
stage I-III disease. Among patients with stage III disease,
there was a 10% absolute improvement in failure-free
survival and 12.5% improvement in OS with combined
chemoradiation therapy compared with RT alone.8 The
Gynecologic Oncology Group (GOG) 258 trial evaluated
the benefit of chemoradiation therapy over chemotherapy

alone for stage III and IVA EC. The addition of RT to
chemotherapy did not result in longer relapse-free survival
at 5 years. The distant relapse rate was higher in patients
who received upfront chemoradiation therapy compared
with systemic chemotherapy alone, although vaginal and
nodal recurrence rates were lower with the addition of
adjuvant RT.9
Given the importance of both systemic and local therapies, national guidelines recommend multimodality approaches for stage IIIC EC10,11; however, the optimal
sequencing of chemoradiation therapy remains controversial. As such, no prospective trial has compared different
sequencing approaches. The purpose of this study was to
evaluate clinical outcomes by the sequence and type of
adjuvant chemoradiation therapy for patients with stage
IIIC EC.

Methods and Materials
In a multi-institutional retrospective cohort study, clinical,
surgical, and pathologic data from 13 academic centers
were collected from September 1995 to July 2019 for patients with International Federation of Obstetrics and Gynecology (FIGO) 2009 stage IIIC EC after local
institutional review board approval. Eligibility required
surgical staging and receipt of adjuvant chemotherapy and
RT. Patients with no recorded nodal sampling, those with
carcinosarcoma histology, those who did not receive both
adjuvant chemotherapy and RT, and those who received
neoadjuvant chemotherapy were ineligible. The final patient cohort included 686 patients eligible for analysis.
Patients with nodal and/or vaginal residual disease were
included.
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Surgical staging consisted of hysterectomy with
salpingo-oophorectomy and lymph node assessment with or
without pelvic washings. Treatment details including type
of chemotherapy, number of concurrent and/or systemic
chemotherapy cycles, radiation modality (external beam RT
[EBRT], vaginal brachytherapy [BT]), radiation field
extent, and delivered dose were recorded.
Adjuvant treatment regimens were classified by
sequence type as adjuvant chemotherapy followed by
sequential EBRT (upfront chemo), concurrent chemoradiation (EBRT) followed by chemotherapy (concurrent),
systemic chemotherapy before and after EBRT (sandwich),
adjuvant EBRT followed by chemotherapy (upfront RT), or
chemotherapy delivered concurrent with vaginal cuff BT
alone (chemo-brachy). The selection criteria for each
sequencing approach was at the discretion of the physician
and in line with each institution’s practice.

Statistical analysis
Descriptive statistics were used to characterize baseline
clinical and treatment characteristics with comparison by
c2 or Fisher’s exact test for the adjuvant sequence groups.
OS was defined from surgery date to death of any cause.
Recurrence-free survival (RFS) was defined from surgery
date to date of first recurrence or progression or last followup. Time to endpoints were calculated by the Kaplan-Meier
method. Recurrences were categorized into 4 categories:
vaginal recurrence only, pelvic  vaginal recurrences,
paraortic lymph node (PALN)  pelvic recurrences, and
distant recurrences  pelvic and PALN recurrences.
Univariable and multivariable analyses were performed
by Cox proportional hazard models for RFS/OS. The variables that were significant (P < .10) on univariate analysis
(UVA) were included in the multivariate analysis. Covariates evaluated by UVA were age, race, histology, tumor
grade, FIGO 2009 stage, presence of 2 or more positive
nodes, presence of adnexal and cervical involvement,
lymphovascular invasion (LVSI), type and sequencing of
adjuvant chemoradiation therapy, radiation field extent, and
time from surgery to radiation as a continuous and
dichotomous variable. Stepwise selection based on Akaike
information criterion was used for model building. The
Fine-Gray model was used to analyze the time to recurrence, and deaths without recurrence were considered
competing risk events. Statistical analyses were conducted
using Microsoft R Open 3.5.3 (https://mran.microsoft.com/)
and SPSS version 27.

Results
Patient characteristics
A total of 686 eligible patients with stage IIIC EC were
identified, and median follow-up was 45.3 months (interquartile range, [IQR] 23.4-71 months). Baseline
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characteristics of the patients are summarized in Table 1.
Data were available and were collected for over 96% of
total patients. The EBRT field size (pelvic vs extended
field) was missing for 96 patients; the latter is explained by
the fact that some patients were treated at community/
regional centers and some data were unavailable for
analysis.
Median age at diagnosis was 62 years (IQR, 55-70).
Most patients had FIGO stage IIIC1 disease (64%), endometrioid histology (66%), and received a median number of
6 cycles of chemotherapy (71%). Pelvic nodal assessment
was performed in 100% of patients, and pelvic and paraortic lymph node assessment was performed in 64.5% of
patients (n Z 443). A small percentage of patients (8%)
had gross residual disease after surgery, mostly nodal (7%),
and 1% had pelvic disease. Upfront chemo was the most
common sequencing regimen (42.5%), followed by
“sandwich” (25%) and concurrent regimens (16.5%). Most
patients (58.5%) were treated with combination of EBRT
and vaginal cuff BT, whereas 13.7% received BT alone.
The proportion of PALN assessment was highest for patients treated with chemo-brachy (82%) and upfront RT
(79%) and lowest for patients treated with the concurrent
regimen (56%) (P Z .002). BT was mostly but not exclusively delivered to patients with cervical involvement. Of
the 249 patients with cervical involvement, 172 (69%)
patients were treated with combination of EBRT and BT,
and 225 patients (52%) without cervical involvement
received a combination of EBRT and BT.
Age, race, depth of myometrial invasion, LVSI, number
of positive lymph nodes, adnexal and cervical involvement,
and stage were well balanced among all treatment
sequencing arms (Table 1, all P > .05).
However, histology and grade were significantly
different between the chemoradiation therapy sequencing
arms. There were more endometrioid histologies in the
concurrent arm (78% vs 61%-73% in the other sequencing
arms), whereas there were more nonendometrioid histologies in the sandwich and chemo-brachy arms (36% and
39% vs 22% in concurrent, P Z .025). There were
significantly more grade 3 tumors in the sandwich treatment arm (60% vs 38%-54% in the other arms) (P Z .002).

Treatment characteristics
The most commonly used chemotherapy regimen was
carboplatin (area under the curve Z 6) and paclitaxel (175
mg/m2) every 3 weeks (89%). The median number of cycles delivered was 6 (IQR, 5-6). Other regimens included
taxotere/adriamycin/cyclophosphamide,
adriamycin/
cisplatin, and platinum-based chemotherapy. Cisplatin was
mainly used in combination with radiation. Most patients
(79%) treated with concurrent chemoradiation received a
total of 2 cycles of cisplatin while 15% of patients received
cisplatin weekly followed by a median of 4 (IQR, 4-6)
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Table 1

Distribution of risk factors among the chemoradiation therapy sequencing arms

58 (75%)
Age, median (IQR), y
<60
60
Race
Nonblack
Black
Histology
Endometrioid
Nonendometrioid
Clear cell Ca
Serous Ca
Mixed Ca
Mucin Ca
Squamous cell Ca
Grade
1-2
3
Depth of myometrial
invasion
<50%
50%
LVSI
Absent
Present
No. of positive
lymph nodes
<2
2
Adnexal involvement
Absent
Present
Cervical involvement
Absent
Present
FIGO stage
IIIC1
IIIC2
Radiation treatment
EBRT
BT
Both
Sequence of
chemotherapy and RT
Upfront chemo
Concurrent
Sandwich
Upfront RT
Chemo-brachy
Median no. of
chemotherapy
cycles (IQR)

Entire cohort
n Z 686

Upfront chemo
n Z 292

62 (55-70)
280 (41%)
406 (59%)

131 (45%)
161 (55%)

42 (37%)
71 (63%)

68 (40%)
102 (60%)

15 (44%)
19 (56%)

24 (31%)
53 (69%)

.25

568 (83%)
90 (13%)

284 (89%)
30 (11%)

96 (85%)
17 (15%)

122 (72%)
31 (18%)

29 (85%)
4 (12%)

67 (87%)
8 (11%)

.025

451
235
23
130
70
5
1

187 (64%)
105 (36%)

88 (78%)
25 (22%)

104 (61%)
66 (39%)

25 (73.5%)
9 (26.5%)

47 (61%)
30 (39%)

.025

328 (48%)
354 (52%)

132 (46%)
157 (54%)

69 (62%)
43 (38%)

68 (40%)
102 (60%)

19 (56%)
15 (44%)

40 (52%)
37 (48%)

.002

194 (28%)
491 (72%)

84 (29%)
208 (71%)

21 (19%)
92 (81%)

55 (32%)
115 (68%)

8 (23.5%)
25 (73.5%)

26 (34%)
51 (66%)

.07

145 (21%)
529 (77%)

55 (19%)
231 (81%)

28 (25.5%)
82 (74.5%)

34 (20%)
134 (80%)

9 (26.5%)
24 (70.5%)

19 (25%)
58 (75%)

.4

267 (39%)
419 (61%)

118 (40%)
174 (56%)

49 (43%)
64 (57%)

52 (31%)
118 (69%)

12 (35%)
22 (65%)

36 (47%)
41 (53%)

.07

546 (81%)
126 (19%)

222 (78%)
62 (22%)

89 (80%)
22 (20%)

147 (87.5%)
21 (12.5%)

29 (85%)
3 (9%)

59 (77%)
18 (23%)

.1

429 (62.5%)
249 (36.5%)

191 (65%)
101 (35%)

76 (67%)
37 (33%)

103 (61%)
67 (39%)

21 (62%)
13 (38%)

48 (62%)
28 (36%)

.7

439 (64%)
247 (36%)

191 (65%)
101 (35%)

76 (67%)
37 (34%)

108 (63.5%)
62 (36.5%)

22 (65%)
12 (35%)

42 (54.5%)
35 (45.5%)

.4

191 (28%)
94 (14%)
401 (58%)

45 (15%)
14 (5%)
233 (79%)

43 (38%)
0
70 (62%)

90 (53%)
1 (0.6%)
79 (46.4%)

13 (38%)
2 (6%)
19 (56%)

0
77 (100%)
0

6 (5-6)

4 (4-6)

6 (4-6)

6 (6-6)

292
113
170
34
77
6

(66%)
(34%)
(3.4%)
(19.3%)
(10.3%)
(0.7%)
(0.15)

(42.5%)
(16.5%)
(25%)
(5%)
(11%)
(5-6)

Concurrent
n Z 113

Sandwich
n Z 170

6 (6-6)

Upfront RT
n Z 34

Chemo-brachy
n Z 77

P value

<.0001

NS

Abbreviations: BT Z brachytherapy; Ca Z carcinoma; EBRT Z external beam radiation therapy; IQR Z interquartile range 25th-75th percentile;
LVSI Z lymphovascular invasion; NS Z not significant; RT Z radiation therapy.
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and 1 death was related to treatment. As for recurrences, a
total of 201 (29%) occurred in the entire cohort: 84 (29%)
recurrences in the upfront chemo group, 30 (26.5%) in the
concurrent group, 51 (30%) in the sandwich group, 11
(32%) in the upfront RT group, and 25 (32.5%) in the
chemo-brachy group (P Z .89).
The estimated 5-year OS and RFS rates for the entire
cohort were 74% and 66%, respectively. For endometrioid
histology, the estimated 5-year RFS and OS were 74.4%
and 83.6%, compared with 48.8% and 55.7% for nonendometrioid histology, respectively (P < .0001). By tumor
grade, the estimated 5-year RFS and OS for patients with
grade 1-2 tumors were 81.1% and 86.6%, compared with
50.0% and 59.2% for grade 3 disease, respectively
(P < .0001).
On UVA for OS, older age, nonwhite race, nonendometrioid histology, grade 3 tumor, 2 or more positive
nodes, deep myometrial invasion, adnexal involvement,

adjuvant chemotherapy cycles. No difference in compliance was seen between the different sequencing groups.
EBRT was delivered 5 days a week with a median dose
of 45 Gy (range, 21.6-55 Gy) in 25 fractions (range, 12-32
fractions). Intracavitary vaginal high-dose-rate BT alone
(without EBRT) was delivered to a median dose of 14 Gy in
2 fractions (12-30 Gy, 2-5 fractions) and to a median dose
of 12 Gy in 3 fractions (5-32.5 Gy, 1-6 fractions) with
EBRT.

Outcomes
A total of 168 deaths were reported for the entire cohort: 71
(24%) deaths in the upfront chemo group, 25 (22%) in the
concurrent group, 36 (21%) in the sandwich group, 10
(29%) in the upfront RT group, and 26 (34%) in the chemobrachy group (P Z .25). Among the 168 deaths, 124 (74%)
were related to EC, 31 (18%) were not related to disease,

Table 2

5

Summary of univariate and multivariate analysis for survival endpoints
UVA for OS

MVA for OS

UVA for RFS

MVA for RFS

HR

P value

HR

Variable

HR (unadjusted)

P value

HR

P value

P value

Time from surgery to radiation:
Increase by 1 wk
Age:
60 vs <60 y
Histology:
Nonendometrioid vs endometrioid
Race:
Black vs nonblack
Grade:
3 vs 1-2
Stage:
IIIC2 vs IIIC1
Presence or absence of PALN dissection
No. of positive nodes:
2 vs <2
> 1 vs  1 positive PALN
Depth of myometrial invasion:
50% vs <50%
Adnexal involvement:
Present vs absent
Cervical involvement:
Present vs absent
LVSI:
Present vs absent
Type of sequencing
Concurrent vs upfront chemo
Sandwich vs upfront chemo
Upfront RT vs upfront chemo
Chemo-brachy vs upfront chemo
Radiation type
EBRT vs BT
EBRT vs BT þ EBRT

0.987

.030

NSFM

N/A

0.99

.22

NSFM

N/A

1.625

.003

NSFM

N/A

1.328

.05

NSFM

N/A

2.743

<.0001

1.614

.012

2.2

<.0001

NSFM

N/A

2.557

<.0001

1.986

.001

1.8

.001

1.527

.023

3.417

<.0001

2.017

.001

3.06

<.0001

2.548

.000

1.614

.002

1.454

.021

1.51

.003

1.469

.010

1.2
1.623

.64
.004

NSFM
NSFM

N/A
N/A

1.05
1.29

.64
.076

NSFM
NSFM

N/A
N/A

2.04
1.528

<.0001
.024

NSFM
1.344

N/A
.141

1.65
1.419

.003
.034

NSFM
NSFM

N/A
N/A

1.904

<.0001

1.706

.003

1.81

<.0001

1.550

.010

1.816

<.0001

1.404

.046

1.69

<.0001

1.425

.021

1.402

.094

NSFM

N/A

1.36

.089

NSFM

N/A

1.26
1.11
1.06
1.28

.3
.59
.83
.27

NSFM

N/A

1.03
1.1
1.07
1.12

.88
.38
.81
.6

NSFM

N/A

1.02
0.86

.9
.4

NSFM

N/A

.99
1.1

.9
.4

NSFM

N/A

Abbreviations: BT Z brachytherapy; EBRT Z external beam radiation therapy; HR Z hazard ratio; LVSI Z lymphovascular space invasion; MVA Z
multivariate analysis; N/A Z not applicable; NSFM Z not selected in final model; OS Z overall survival; PALN Z paraortic lymph node; RFS Z
recurrence-free survival; UVA Z univariate analysis.
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cervical involvement, and stage IIIC2 versus IIIC1 were
associated with worse OS, as shown in Table 2.
A total of 44 deaths without recurrence were considered
as competing risk events and were considered in the analysis of RFS. On UVA for RFS, older age, nonwhite race,
nonendometrioid histology, grade 3 tumor, pelvic and
PALN EBRT field versus pelvic field, deep myometrial
invasion, LVSI, adnexal involvement, cervical involvement,
and stage IIIC2 were associated with recurrence. More than
1 positive PALN (P Z .03) was significantly associated
with lower RFS rate and lower OS (P < .0001) rates.
The presence or absence of PALN assessmentwas not
associated with OS or RFS.
The factors significantly associated with OS and RFS on
multivariate analysis were race, histology, grade, stage,
adnexal involvement, and cervical involvement (all P <
.05). Specifically, black race, nonendometrioid histology,
grade 3, stage IIIC2, and presence of adnexal and cervical
involvement were associated with recurrence and worse
survival (Table 2).

Sequencing and type of adjuvant therapy

Survival probability

The sequence and type of adjuvant therapy (upfront chemo
vs concurrent vs sandwich vs upfront RT vs chemo-brachy)
were not associated with hazard of OS or RFS (Table 2 and
Figs. 1 and 2). As for the type of radiation delivered,
(EBRT vs BT vs both), no association was found with
hazard of OS and RFS. To overcome the imbalances between the different chemoradiation therapy arms, a stratified subgroup analysis was done for histology and for
grade. The sequence and type of adjuvant therapy as well as
the type of RT were not correlated with OS or RFS for
endometrioid versus nonendometrioid histologies and for
grade 1-2 versus 3.
A second subgroup analysis was performed excluding
patients treated with chemo-brachy and upfront RT to
strengthen the analysis and evaluate the 3 main sequencing

1.00

Treatment
upfront chemo
concurrent
sandwich

0.75

upfront RT
chemo-brachy

0.50

0.25
P = .78

0.00
0

50

100

150

200

months

Fig. 1. Estimated overall survival (OS) Kaplan-Meier
curves by sequencing type.

approaches (upfront chemo, concurrent, and sandwich).
There were no differences in OS and RFS among the 3
main sequencing approaches.

Factors associated with site of first recurrence
The most common site of first recurrence was distant
metastasis (20.1%). Vaginal-only recurrence occurred in 11
patients (1.6%), and pelvic-only recurrence occurred in 15
patients (2.2%). Pelvic and vaginal recurrences occurred in
4 patients (0.6%) and PALN recurrences  pelvic and
vaginal recurrences occurred in 43 patients (6.3%). BT
alone was associated with a higher rate of PALN  pelvic
recurrence (15%) compared with EBRT or the combination
of EBRT and BT (5%) (P < .0001).

Discussion
This large multi-institutional study evaluated the importance of adjuvant chemotherapy and RT sequence in a
cohort of 686 patients with stage IIIC EC. After a median
follow-up of 45.3 months, no statistically significant difference was detected among 5 different sequencing regimens in terms of RFS and OS. Known prognostic factors,
including black race, nonendometrioid histology, grade 3
tumor, stage IIIC2 disease, and presence of adnexal and
cervical involvement, were associated with worse OS and
RFS rates on multivariate analysis. Our results compare
favorably with those of phase 3 randomized trials. Notably,
the estimated 5-year RFS rate for this cohort was 74%,
which compares favorably with the PORTEC 3 stage III
subgroup (78.5%)8 and the results of GOG-258 (59%).9 In
addition, similar to PORTEC 3, distant metastasis was the
most common site of recurrence.
Combination chemoradiation therapy has been shown to
yield superior long-term outcomes for locally advanced EC
compared with a single modality approach.8-11 Although
the GOG-258 trial did not demonstrate a recurrence-free or
survival benefit with the addition of RT to chemotherapy
alone, patients who received chemotherapy alone had
higher rates of vaginal (7% vs 2%) and pelvic and PALN
recurrence (20% vs 11%),9 which supports the role of
adjuvant RT in preventing vaginal or nodal recurrence. In
our study, the vaginal, pelvic, and PALN recurrence rates
(without distant metastasis) were very low (1.6%, 2.2%,
6.3%) with chemoradiation therapy, highlighting the
importance of adjuvant RT in pelvic control. Given the
need to reduce the risk of distant metastasis while maximizing pelvic control in patients with stage IIIC EC,
various sequencing regimens have been studied, with the
rationale of using upfront chemotherapy to maximize
distant control and upfront radiation to maximize pelvic
control. The sandwich regimen is a compromise between
the 2 approaches, although the regimen entails a break in
systemic chemotherapy during the adjuvant RT course.
There are no prospective trials that evaluate the importance
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of adjuvant chemotherapy and RT sequence. Few studies
have reported good clinical outcomes with “Sandwich”
chemotherapy and RT while others reported on concurrent
chemoradiation followed by additional chemotherapy18,19
or RT upfront followed by chemotherapy.20 The concurrent regimen was initially evaluated in a phase 2 Radiation
Therapy Oncology Group study with excellent reported
clinical results18 and was adapted as the experimental arm
in the GOG-258 and PORTEC-3 studies. A major criticism
of the concurrent regimen is the delay in the delivery of
systemic doses of chemotherapy, which may have been
responsible for the higher rate of distant metastasis
observed in the concurrent arm of the GOG-258 study.18
When comparing treatment sequence, small retrospective studies have shown no difference in outcomes between
upfront chemotherapy followed by adjuvant RT and the
sandwich regimen for stage III EC.21,22 The sandwich
regimen was found to be feasible and well tolerated,
although it was associated with more hematologic toxicity
and treatment breaks than upfront chemotherapy followed
by RT.15,23,24 A National Cancer Data Base study evaluated
survival outcomes in women with node-positive EC
receiving different sequencing of adjuvant therapy. A total
of 1826 patients with a median follow-up of 49.2 months
were analyzed. The 5-year OS rate was significantly higher
for upfront chemotherapy followed by RT compared with
concurrent chemoradiation (67% vs 62%, P Z .004),
although the findings are limited by the study’s retrospective nature and absence of a cancer-specific survival
endpoint.26
Another observational cohort study reported on the
optimal management of stage III-IV type 1 (grade 1-2
endometrioid) EC. A total of 5795 women were identified,
of whom 1260 (21.7%) received EBRT only, 2465 (42.5%)
received chemotherapy only, 593 (9.7%) received upfront
EBRT before chemotherapy, and 1506 (26.0%) received
upfront chemotherapy followed by EBRT. Upfront
chemotherapy followed by EBRT was associated with
longer OS compared with single-modality EBRT or
chemotherapy or upfront EBRT followed by chemotherapy.25 Although upfront chemotherapy followed by
EBRT was associated with improved OS for patients with
advanced stage grade 1-2 endometrioid cancers, these
observational studies have limitations: OS is the only
outcome available in observational studies, and cancerspecific survival outcomes and details on locoregional and
distant recurrences are not reported. In addition, treatment
details including dose, fractionation, and number of
chemotherapy cycles planned and delivered are not available. When a stratified survival analysis restricted to patients with grade 1-2 endometrioid tumors was performed
in this cohort, adjuvant therapy sequence was not associated with recurrence or survival.
In the subset of patients treated with vaginal BT alone in
conjunction with chemotherapy, these patients were largely
from an era in which surgical staging yielded on average 20
to 30 nodes, and the fear of toxicity from 3-dimensional
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Fig. 2. Estimated recurrence-free survival (RFS) KaplanMeier curves by sequencing type.
conformal pelvic  PALN RT outweighed its presumed
benefit. However, given the very large number of locoregional failures (PALN  pelvic recurrences) in the absence
of EBRT (15% vs 5%) in this series, and in conjunction
with the significant advances in surgical technique
including use of sentinel nodes for staging, along with
routine adaptation of intensity modulated RT resulting in
improved tolerance and toxicity, this practice has fallen out
of favor, and regional nodal treatment with pelvic  PALN
has become standard.
Despite having the strength of a large multi-institutional
cohort with robust follow-up, our study has several limitations. First, it is a retrospective study with inherent selection bias and heterogenous patient population.
Additionally, toxicity data were not available from all
participating institutions because the main goal was to
evaluate the effect of chemoradiation therapy sequencing
approaches on survival endpoints. Toxicity is very important, especially in the context of similar clinical outcomes,
and will be addressed in a future research project.
Although all patients had stage IIIC EC, endometrioid
and nonendometrioid histologies were included. Five
different types of chemotherapy and RT sequencing approaches were included, which reflects the current practice
across several institutions and adds to the controversy
pertaining to the appropriate approach. The treatment arms
were not balanced for all prognostic factors: The concurrent
regimen had more patients with endometrioid histologies,
whereas the sandwich and chemo-brachy regimens had
more nonendometrioid histologies than the other arms.
There were also significantly more grade 3 tumors in the
sandwich treatment arm. The date of surgery was used as
time zero to estimate the OS and RFS. The start date of
chemotherapy and/or RT were not available for all patients
because a large proportion of patients were referred to the
academic center/main campus for part of their treatment.
The authors acknowledge the controversial choice of
selecting date of surgery as time zero in a retrospective
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study. Finally, our study is unlikely to be powered to detect
survival differences among the various sequencing
regimens.
No randomized trial has yet evaluated the optimal
sequencing approach for stage IIIC EC. Our study is the
largest retrospective multi-institutional study reporting on
the effect of adjuvant chemoradiotherapy sequencing on
clinical outcomes for stage IIIC EC. This study represents
the practice of 13 academic institutions across the United
States between 1995 and 2019. Indeed, the locoregional
recurrence rates of this study are similar to those of the
GOG-258 concurrent chemoradiation therapy arm, and the
distant recurrence rate is similar to the chemotherapy only
arm,9 again emphasizing the importance of both modalities.
Despite use of adjuvant chemotherapy and radiation, distant
recurrence remains the most common site of recurrence,
and systemic regimens are needed given the clinical and
biological heterogeneity of EC.

Conclusions
The sequence and type of combined adjuvant therapy did
not affect OS or RFS rates, which were comparable to those
of the prospective GOG 258 and PORTEC-3 studies. The
prognostic risk factors for stage IIIC EC were race, histology, grade, stage, adnexal involvement, and cervical
involvement. Adjuvant chemoradiation therapy resulted in
excellent pelvic control. This was similar to that achieved
by the randomized concurrent chemoradiation studies,
confirming the efficacy of this regimen. BT alone was
associated with a higher rate of PALN recurrence, emphasizing the role of nodal EBRT in stage IIIC EC. The vast
proportion of recurrences were distant, despite systemic
chemotherapy given early in the majority of patients,
highlighting the need for novel systemic regimens to
further improve outcomes.
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